Bright Minds Biosciences Inc.

DRUG · Nasdaq · United States

Share price · DRUG

$20.76-63.28 (-75.30%) 3M

close as of 2026-11-18 · 24h delayed · vol 135K (0.5x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when DRUG's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 3 Nov 2026-17.7%
  2. 2 Nov 2026-52.3%
  3. 21 Oct 2026-8.6%

    Nothing announced by DRUG that day or the session before.

  4. 7 Oct 2026+7.8%

    Nothing announced by DRUG that day or the session before.

  5. 24 Sep 2026-7.6%

    Nothing announced by DRUG that day or the session before.

  6. 9 Jul 2026+11.9%

    Nothing announced by DRUG that day or the session before.

  7. 8 Jul 2026+8.1%

    Nothing announced by DRUG that day or the session before.

  8. 10 Jun 2026-9.2%

    Nothing announced by DRUG that day or the session before.

  9. 1 Jun 2026-8.0%

    Nothing announced by DRUG that day or the session before.

  10. 20 May 2026+11.1%

Share of unusual movement by asset

For each asset, the share of DRUG's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
BMB-101
events and moves
90%
Other company news (earnings, financing, releases naming no asset)—97%
Sessions with no dated event—2%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
Serotonin 5-HT2C receptor (biased agonist)Small molecule
EpilepsyDevelopmental and Epileptic Encephalopathies
Absence Seizures

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
November 2026 (1)
BMB-101Phase 2Prader-Willi Syndrome
Est. primary completion 2026-11 · NCT07266324 · CT.gov ↗
What to watch
December 2026 (1)
2026-09-30 Financial ReportEarnings report
Expected report date 2026-12-22 · Fiscal period ending 2026-09-30
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

6 January 2026Topline resultBMB-101Phase 2 BREAKTHROUGH of BMB-101 reported positive topline results in absence seizures and DEE
Bright Minds Biosciences Inc. · Source ↗

Financial reports

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$0.9M$4.2M$0.5M-$1.4M operating cash flowreport ↗
View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-FY—$3.7M$5.0M$1.4M-$5.2M operating cash flowreport ↗
2022-FY—$9.5M$8.4M$2.9M-$11M operating cash flowreport ↗
2021-FY—$5.0M$16M$1.7M-$5.8M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 1 sale ($9.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-04-28Cormorant Asset Management, LP; Chen Bihua; Cormorant Global Healthcare Master Fund, LP · Former 10% Owner; Former 10% Owner; Former 10% OwnerOpen-market sale109,331$89.50$9.8MForm 4
2024-11-04Cormorant Asset Management, LP; Chen Bihua · 10% owner; 10% ownerOpen-market purchase184,331$21.70$4.0MForm 4
2024-10-16Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Chen Bihua · 10% owner; 10% owner; 10% ownerOpen-market purchase39,743$23.21$923KForm 4
2024-10-16Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Chen Bihua · 10% owner; 10% owner; 10% ownerOpen-market purchase7,150$24.03$172KForm 4
2024-10-16Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Chen Bihua · 10% owner; 10% owner; 10% ownerOpen-market purchase3,107$25.22$78KForm 4
2024-10-15Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Chen Bihua · 10% owner; 10% owner; 10% ownerOpen-market purchase238,097$4.53$1.1MForm 4
2024-10-15Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Chen Bihua · 10% owner; 10% owner; 10% ownerOpen-market purchase63,173$5.92$374KForm 4
2024-10-15Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Chen Bihua · 10% owner; 10% owner; 10% ownerOpen-market purchase33,343$6.42$214KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 93 reporting institutions held 9.2M shares ($669.7M).

#InstitutionSharesValue
1JANUS HENDERSON GROUP PLC1,284,324$93.5M
2Cormorant Asset Management, LP1,059,331$77.3M
3BlackRock, Inc.621,933$45.4M
4Vivo Capital, LLC557,172$40.7M
5BRAIDWELL LP539,708$39.4M
6ADAGE CAPITAL PARTNERS GP, L.L.C.495,743$36.2M
7Vestal Point Capital, LP492,319$35.9M
8Driehaus Capital Management LLC432,515$31.6M
9PERCEPTIVE ADVISORS LLC377,544$27.5M
10Balyasny Asset Management L.P.297,158$21.7M
11DEERFIELD MANAGEMENT COMPANY, L.P.283,000$20.7M
12RA CAPITAL MANAGEMENT, L.P.265,000$19.3M
13GREAT POINT PARTNERS LLC220,000$16.1M
14MPM BIOIMPACT LLC212,175$15.5M
15Ikarian Capital, LLC166,647$12.2M